相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer
Ying Cheng et al.
ONCOLOGY LETTERS (2019)
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
T. K. Owonikoko et al.
ANNALS OF ONCOLOGY (2019)
Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential
Samantha A. Armstrong et al.
ADVANCES IN THERAPY (2019)
IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
M. Reck et al.
ANNALS OF ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies
Hyun Cheol Chung et al.
CANCER RESEARCH (2019)
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)
Shadia I. Jalal et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial
In-Jae Oh et al.
BMC CANCER (2016)
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Yan Sun et al.
BMC CANCER (2016)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer
Ikuo Sekine et al.
CLINICAL LUNG CANCER (2014)
Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509
Miyako Satouchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer Final Results of a Randomized Phase III Trial
Thomas H. Fink et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer
A. Schmittel et al.
ANNALS OF ONCOLOGY (2011)
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
P. Zatloukal et al.
ANNALS OF ONCOLOGY (2010)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
S. Baka et al.
BRITISH JOURNAL OF CANCER (2008)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: Preliminary results of a phase III trial of the Hellenic Oncology Research Group
Michail Ignatiadis et al.
CLINICAL LUNG CANCER (2005)
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and leukemia group B trial 9732
HB Niell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up
S Sundstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group
JH Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
D Mavroudis et al.
ANNALS OF ONCOLOGY (2001)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
C Mascaux et al.
LUNG CANCER (2000)
分享论文
